Lucia MessingerovaAfter completing her studies, Dr. Messingerova started working at the Slovak Technical University, Faculty of Chemical and Food Technology, as well as at the Slovak Academy of Sciences in the Centre for Biosciences, where she leads a team dealing wit the development of resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In her work, she focuses on changes in apoptotic pathways, transport, and metabolism of HMAs in sensitive and resistant AML cell lines. The goal of her team's work is to identify an easily and quickly detectable marker of response to HMA treatment, since it is known that after the failure of this treatment in patients unsuitable for intensive therapy, only the possibility of inclusion in clinical trials or palliative care remains. Read More Read Less